A Phase 3 interventional study of Lenvatinib and Placebo in Thyroid Cancer, sponsored by Eisai Inc.. Completed at 155 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lenvatinib in Thyroid Neoplasms — 6 open to participants now, 7 under way, none of them phase 3. lenvatinib · Thyroid Neoplasms.
Among the 17 studies testing lenvatinib in Thyroid Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2011, is one of 2 in phase 3, and was the 2nd registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →6 of the 17 studies testing lenvatinib in Thyroid Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Fudan University · Sites in China
Fujian Medical University · Sites in China
Ages 18–80
Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
17 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 392 is above the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 35 across the 17 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
10 studies in Thyroid Neoplasms by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 10 studies in Thyroid Neoplasms by Eisai Co., Ltd., this one is the only one that started in 2011, is one of 2 in phase 3, and was the 3rd registered.
Eisai Co., Ltd.’s Thyroid Neoplasms studies by the year they started, since 2005.
3 of the studies testing lenvatinib in Thyroid Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06195228Fudan UniversityA Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer | 2026-12-31 |
| NCT06848920Zhejiang UniversityStudy of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma | 2027-06-30 |
| NCT04171622M.D. Anderson Cancer CenterLenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing lenvatinib in Thyroid Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 10 in Thyroid Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).
Randomization Phase: Participants will receive blinded study drug (lenvatinib/placebo) in 2:1 ratio until documentation of disease progression (confirmed by independent imaging review), development of unacceptable toxicity, or withdrawal of consent. After having completed the primary analysis, subjects treated with lenvatinib who have not experienced disease progression may request to continue open label lenvatinib at the same dose, according to the clinical judgment of the investigator. Participants who discontinue treatment for any reason other than disease progression will be followed in the Randomization Phase until disease progression or start of another anticancer treatment; these participants then enter the Extension Phase for survival follow-up. Extension Phase: Participants in the placebo arm who have disease progression confirmed by IIR could request to enter the OOL Lenvatinib Treatment Period and receive lenvatinib treatment. Participants will receive lenvatinib treatment until disease progression (investigator's assessment), development of intolerable toxicity, or withdrawal of consent. Participants who had disease progression during the Randomization Phase and did not enter the OOL Lenvatinib Treatment Period and all participants who discontinued lenvatinib treatment in the OOL Lenvatinib Treatment Period will enter the follow-up period. Participants will be followed for survival, and all anticancer treatments will be recorded until the time of death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Inclusion criteria for OOL Lenvatinib Treatment Period :
Participants were eligible for lenvatinib treatment in the OOL Lenvatinib Treatment Period if the met the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
Drug: Lenvatinib
Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
Drug: Placebo
Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
Drug: Lenvatinib
Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
Drug: Lenvatinib
Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
Also known as: Lenvatinib (Lenvima, E7080)
Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity. The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg.
Also known as: Lenvatinib (Lenvima, E7080)
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded IIR using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.
Time frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Overall Response Rate (ORR)
ORR, defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.
Time frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Overall Survival (OS)
Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.
Time frame: Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve
Time frame: Cycle 1 Days 1 and 15: 0-10 hours postdose; Cycle 2 Day 1: 0-12 hour postdose
Participants took part in the study at 117 investigative sites in Europe, North America, Asia Pacific, Japan, and Latin America from 17 March 2011 to 19 March 2019.
| Milestone | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo | OOL, Treatment Period: Lenvatinib 24 mg | OOL, Treatment Period: Lenvatinib 20 mg |
|---|---|---|---|---|
| Started | 261 | 131 | 0 | 0 |
| Completed | 261 | 131 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo | OOL, Treatment Period: Lenvatinib 24 mg | OOL, Treatment Period: Lenvatinib 20 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 85 | 30 |
| Completed | 0 | 0 | 85 | 30 |
| Not completed | 0 | 0 | 0 | 0 |
PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded IIR using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.
| months | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo |
|---|---|---|
| Progression Free Survival (PFS) | 18.3 (15.1 to NA) | 3.6 (2.2 to 3.7) |
ORR, defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.
| percentage of participants | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo |
|---|---|---|
| Overall Response Rate (ORR) | 64.8 (59.0 to 70.5) | 1.5 (0.0 to 3.6) |
Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.
| months | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo |
|---|---|---|
| Overall Survival (OS) | NA (22.0 to NA) | NA (14.3 to NA) |
| nanogram*hour per milliliter (ng*h/mL) | Randomization Phase: Lenvatinib 24 mg |
|---|---|
| Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve | 3490 (1410 to 10700) |
Collected over For each participant, from the first dose till 30 days after the last dose up to approximately 8 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomization Phase: Lenvatinib 24 mg | 161/261 (61.7%) | 171/261 (65.5%) | 259/261 (99.2%) |
| Randomization Phase: Placebo | 13/16 (81.3%) | 31/131 (23.7%) | 118/131 (90.1%) |
| OOL, Treatment Period: Lenvatinib 24 mg | 62/85 (72.9%) | 62/85 (72.9%) | 84/85 (98.8%) |
| OOL, Treatment Period: Lenvatinib 20 mg | 15/30 (50%) | 16/30 (53.3%) | 29/30 (96.7%) |
| Event | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo | OOL, Treatment Period: Lenvatinib 24 mg | OOL, Treatment Period: Lenvatinib 20 mg |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/261 | 1/131 | 0/85 | 2/30 |
| Lung infectionInfections and infestations | 4/261 | 0/131 | 1/85 | 2/30 |
| PneumoniaInfections and infestations | 12/261 | 3/131 | 5/85 | 2/30 |
| Abdominal painGastrointestinal disorders | 3/261 | 0/131 | 4/85 | 0/30 |
| HypertensionVascular disorders | 10/261 | 0/131 | 1/85 | 1/30 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/261 | 5/131 | 3/85 | 1/30 |
| Atrial fibrillationCardiac disorders | 4/261 | 0/131 | 3/85 | 0/30 |
| Back painMusculoskeletal and connective tissue disorders | 3/261 | 0/131 | 3/85 | 0/30 |
| Cerebrovascular accidentNervous system disorders | 2/261 | 0/131 | 3/85 | 1/30 |
| DeathGeneral disorders | 2/261 | 1/131 | 3/85 | 0/30 |
| Event | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo | OOL, Treatment Period: Lenvatinib 24 mg | OOL, Treatment Period: Lenvatinib 20 mg |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 182/261 | 22/131 | 55/85 | 21/30 |
| HypertensionVascular disorders | 181/261 | 19/131 | 52/85 | 21/30 |
| Weight decreasedInvestigations | 142/261 | 20/131 | 44/85 | 18/30 |
| Decreased appetiteMetabolism and nutrition disorders | 148/261 | 24/131 | 43/85 | 11/30 |
| NauseaGastrointestinal disorders | 127/261 | 34/131 | 34/85 | 12/30 |
| FatigueGeneral disorders | 116/261 | 33/131 | 35/85 | 13/30 |
| StomatitisGastrointestinal disorders | 100/261 | 9/131 | 28/85 | 13/30 |
| VomitingGastrointestinal disorders | 100/261 | 19/131 | 36/85 | 9/30 |
| HeadacheNervous system disorders | 105/261 | 15/131 | 19/85 | 10/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 85/261 | 9/131 | 19/85 | 12/30 |
| Age, Continuous(years) | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo | Total |
|---|---|---|---|
| Geometric mean | 62.1 ± 10.57 | 61.5 ± 10.09 | 61.9 ± 10.40 |
| Sex: Female, Male(Participants) | Randomization Phase: Lenvatinib 24 mg | Randomization Phase: Placebo | Total |
|---|---|---|---|
| Female | 136 | 56 | 192 |
| Male | 125 | 75 | 200 |
Showing the first 100 of 155 sites across 23 countries. Choose a country and city above to see the rest.
Ran from Mar 2011 to primary completion in Nov 2013, 31 months.
Results were first posted in Dec 2016, 3 years after primary completion.
Of 19 phase 3 interventional studies under Thyroid Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 106. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib